.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A07A_IntestinalAntiinfectives.A07AA07_AmphotericinB.AmphotericinB .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A07A_IntestinalAntiinfectives.A07AA07_AmphotericinB.AmphotericinB| name: | AmphotericinB |
| ATC code: | A07AA07 | route: | intravenous |
| n-compartments | 2 |
Amphotericin B is a polyene antifungal medication used primarily for the treatment of severe systemic fungal infections, including cryptococcal meningitis, aspergillosis, histoplasmosis, and candidiasis. It is considered a drug of last resort due to its nephrotoxicity but remains in use, particularly in immunocompromised patients. Amphotericin B is approved for clinical use and is available in both deoxycholate and lipid formulations.
Pharmacokinetics in adult patients with systemic fungal infections receiving intravenous amphotericin B deoxycholate.
Groll, AH, et al., & Brüggemann, RJM (2019). Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 68(Suppl 4) S260–S274. DOI:10.1093/cid/ciz076 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31222253
Würthwein, G, et al., & Walsh, TJ (2005). Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrobial agents and chemotherapy 49(12) 5092–5098. DOI:10.1128/AAC.49.12.5092-5098.2005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16304177
Nath, CE, et al., & Earl, JW (2001). Population pharmacokinetics of amphotericin B in children with malignant diseases. British journal of clinical pharmacology 52(6) 671–680. DOI:10.1046/j.0306-5251.2001.01496.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/11736878